Auto-generated provisional profile — pending full editorial review.
This agent has a catalog entry, but its citation-grounded monograph has not been written yet. Only verified fields are shown below. Not medical advice.
Defactinib
No direct nephrotoxicity signal in titles; FAK biology renal-relevant but drug-specific injury unestablished
Signature kidney injury
Signature lesion
Renal toxicities, ranked
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Where it strikes· nephron segments & injury signatures
Nephron segments
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Injury signatures
Guidelines & consensus· 13
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references